As new treatments for systemic lupus erythematosus and lupus nephritis enter the armamentarium, revitalizing the management ...

Pharvaris' innovative approach to treating hereditary angioedema (HAE) with deucrictibant. Read here for an investment ...

Inhibrx Biosciences rises on early clinical success; Ozekibart shows promise in colorectal cancer. Read here for an analysis ...

The town of Granite Quarry is inching closer to fully funding Phase 1 of the Granite Civic Park renovation project, with a recent donation from the Cannon Foundation bringing the town within $600,000.

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

The American Academy of Dermatology has updated its guidelines for treating and managing atopic dermatitis with topical and ...

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients ...